230 related articles for article (PubMed ID: 30566230)
21. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
[TBL] [Abstract][Full Text] [Related]
22. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Asghari H; Lancet J
Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
[TBL] [Abstract][Full Text] [Related]
23. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
Int J Hematol; 2024 Mar; ():. PubMed ID: 38532078
[TBL] [Abstract][Full Text] [Related]
24. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
25. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
Krogh-Madsen M; Bender B; Jensen MK; Nielsen OJ; Friberg LE; Honoré PH
Cancer Chemother Pharmacol; 2012 May; 69(5):1155-63. PubMed ID: 22212298
[TBL] [Abstract][Full Text] [Related]
27. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
28. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
[TBL] [Abstract][Full Text] [Related]
29. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Lemoli RM; Montesinos P; Jain A
Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
Villa KF; Ryan RJ; Chiarella M; Louie AC
J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
[No Abstract] [Full Text] [Related]
31. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
Issa GC; Kantarjian HM; Xiao L; Ning J; Alvarado Y; Borthakur G; Daver N; DiNardo CD; Jabbour E; Bose P; Jain N; Kadia TM; Naqvi K; Pemmaraju N; Takahashi K; Verstovsek S; Andreeff M; Kornblau SM; Estrov Z; Ferrajoli A; Garcia-Manero G; Ohanian M; Wierda WG; Ravandi F; Cortes JE
Leukemia; 2020 Nov; 34(11):2914-2924. PubMed ID: 32546726
[TBL] [Abstract][Full Text] [Related]
32. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
[TBL] [Abstract][Full Text] [Related]
33. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
DiPersio JF; Erba HP; Larson RA; Luger SM; Tallman MS; Brill JM; Vuagniaux G; Rouits E; Sorensen JM; Zanna C
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):443-9. PubMed ID: 25842225
[TBL] [Abstract][Full Text] [Related]
34. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.
Donnette M; Hamimed M; Ciccolini J; Berda-Haddad Y; Kaspi E; Venton G; Lacarelle B; Costello R; Ouafik L; Farnault L; Fanciullino R
J Control Release; 2021 Oct; 338():244-252. PubMed ID: 34416320
[TBL] [Abstract][Full Text] [Related]
36. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
37. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
38. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
39. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
